Behrenbruch Christian
SEC insider (Form 3/4/5 filer). CIK 0002037713. MD & Group CEO at Telix Pharmaceuticals Ltd (TLX). 2 reported Form 4/5 transactions since Sep 2024; latest on Apr 29, 2026. Located in NORTH MELBOURNE.
Companies Behrenbruch Christian has filed insider reports for
- Telix Pharmaceuticals Ltd (TLX): Director, Officer, MD & Group CEO
Behrenbruch Christian
CIK: 0002037713
Transaction Breakdown
Open Market Buys (P)2 (100.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
TLX
Telix Pharmaceuticals Ltd
DirectorOfficer